As of November 7, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Nektar Therapeutics. The largest reported stake is Fmr LLC's, at 15%. 22 filings are on record since July 3, 2025 (Schedule 13G/A, May 6, 2026).
Sell to companies like Nektar Therapeutics? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Two Seas Capital LP · Sole voting: 3,345,978 · Shared voting: 0 · Sole dispositive: 3,345,978 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-09-28
- · Reporting person: Biotechnology Value Fund L P · Sole voting: 0 · Shared voting: 1,251,654 · Sole dispositive: 0 · Shared dispositive: 1,251,654 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Two Seas Capital LP · Percent: 9.1% · SCHEDULE 13G/A
- · Reporting person: Vanguard Capital Management · Sole voting: 250,804 · Shared voting: 0 · Sole dispositive: 1,747,653 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-31
- · Reporting person: BlackRock, Inc. · Sole voting: 2,590,855 · Shared voting: 0 · Sole dispositive: 2,643,796 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-29
Nektar Therapeutics has 22 Schedule 13D or 13G filings on record since 2025-07-03. 5 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fmr LLC | 15% | 4,303,188 | SCHEDULE 13G/A, 2026-05-06 | 2026-03-31 |
| Two Seas Capital LP | 9.8% | 3,345,978 | SCHEDULE 13G/A, 2026-09-28 | 2026-09-25 |
| BlackRock, Inc. | 7.8% | 2,643,796 | SCHEDULE 13G, 2026-07-29 | 2026-06-30 |
| Bvf Partners L P | 7.1% | 2,391,075 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Vanguard Capital Management | 5.17% | 1,747,653 | SCHEDULE 13G, 2026-07-31 | 2026-06-30 |
| G1 Execution Services, LLC | 4% | 809,967 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| Millennium Management LLC | 3% | 570,994 | SCHEDULE 13G/A, 2025-10-28 | 2025-09-30 |
| Nantahala Capital Management, LLC | 2.2% | 418,522 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| TCG Crossover GP II, LLC | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Nektar Therapeutics and the warning signs.
Free to see. No signup.
Keep reading
More on Nektar Therapeutics and the records around it.
Nektar Therapeutics elsewhere on the record
- Leadership changes May 2026
- Who owns it
Companies that share a holder
- Two Seas Capital LP also filed stake reports on 14 other companies: Calumet, Inc. (Aug 2026), Quantum Corporation (Aug 2026), Sable Offshore Corp. (Aug 2026)
- TCG Crossover GP II, LLC also filed stake reports on 21 other companies: ALX Oncology Holdings Inc. (Aug 2026), First Tracks Biotherapeutics, Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
- G1 Execution Services, LLC also filed stake reports on 45 other companies: AmpliTech Group, Inc. (Aug 2026), Bitdeer Technologies Group (Aug 2026), Compass Diversified Holdings (Aug 2026)
Watch Nektar Therapeutics
Get an email when Nektar Therapeutics files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Nektar Therapeutics?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Nektar Therapeutics: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Nektar Therapeutics covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
23 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Two Seas Capital LP | 3,345,978 | 0 | 3,345,978 | 0 | SCHEDULE 13G/A, 2026-09-28 |
| Two Seas Capital GP LLC | 3,345,978 | 0 | 3,345,978 | 0 | SCHEDULE 13G/A, 2026-09-28 |
| Sina Toussi | 3,345,978 | 0 | 3,345,978 | 0 | SCHEDULE 13G/A, 2026-09-28 |
| BlackRock, Inc. | 2,590,855 | 0 | 2,643,796 | 0 | SCHEDULE 13G, 2026-07-29 |
| Biotechnology Value Fund L P | 0 | 1,251,654 | 0 | 1,251,654 | SCHEDULE 13G/A, 2026-08-14 |
| Bvf I Gp LLC | 0 | 1,251,654 | 0 | 1,251,654 | SCHEDULE 13G/A, 2026-08-14 |
| Biotechnology Value Fund Ii LP | 0 | 945,732 | 0 | 945,732 | SCHEDULE 13G/A, 2026-08-14 |
| Bvf Ii Gp LLC | 0 | 945,732 | 0 | 945,732 | SCHEDULE 13G/A, 2026-08-14 |
| Biotechnology Value Trading Fund OS LP | 0 | 157,488 | 0 | 157,488 | SCHEDULE 13G/A, 2026-08-14 |
| BVF Partners OS Ltd. | 0 | 157,488 | 0 | 157,488 | SCHEDULE 13G/A, 2026-08-14 |
| Bvf Gp Holdings LLC | 0 | 2,197,386 | 0 | 2,197,386 | SCHEDULE 13G/A, 2026-08-14 |
| Bvf Partners L P | 0 | 2,391,075 | 0 | 2,391,075 | SCHEDULE 13G/A, 2026-08-14 |
| Bvf Inc | 0 | 2,391,075 | 0 | 2,391,075 | SCHEDULE 13G/A, 2026-08-14 |
| Lampert Mark N | 0 | 2,391,075 | 0 | 2,391,075 | SCHEDULE 13G/A, 2026-08-14 |
| Vanguard Capital Management | 250,804 | 0 | 1,747,653 | 0 | SCHEDULE 13G, 2026-07-31 |
The latest filing identifies Nektar Therapeutics by CUSIP 640268306 and gives its principal executive office as 455 Mission Bay Boulevard South, San Francisco, CA 94158 (SCHEDULE 13G/A, 2026-09-28).
What the percentages are based on
Percent of class as of the date hereof: TSC - 9.8% TSC GP - 9.8% Sina Toussi - 9.8% The shares of Common Stock reported for Item 4 total 3,345,978 shares of Common Stock, of which 3,175,430 are held by the Global Fund and 170,548 are held by the Opportunities Fund.Two Seas Capital LP, SCHEDULE 13G/A, 2026-09-28
The following percentages are based on 33,786,032 Shares outstanding as of May 1, 2026, which is the total number of Shares outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2026.Bvf Partners L P, SCHEDULE 13G/A, 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-03 | Millennium Management LLC | 5.4% | SCHEDULE 13G |
| 2025-07-09 | Bvf Partners L P | 7.4% | SCHEDULE 13G |
| 2025-07-18 | BlackRock, Inc. | 1.6% | SCHEDULE 13G/A |
| 2025-08-14 | TCG Crossover GP II, LLC | 9.3% | SCHEDULE 13G/A |
| 2025-08-14 | Nantahala Capital Management, LLC | 5.72% | SCHEDULE 13G |
| 2025-10-28 | Millennium Management LLC | 3% | SCHEDULE 13G/A |
| 2025-10-31 | The Vanguard Group | 4.98% | SCHEDULE 13G/A |
| 2025-11-13 | Susquehanna Portfolio Strategies, LLC | 6.3% | SCHEDULE 13G |
| 2025-11-14 | Nantahala Capital Management, LLC | 2.2% | SCHEDULE 13G/A |
| 2025-11-14 | TCG Crossover GP II, LLC | 0% | SCHEDULE 13G/A |
| 2026-01-30 | The Vanguard Group | 5.04% | SCHEDULE 13G |
| 2026-02-13 | G1 Execution Services, LLC | 4% | SCHEDULE 13G/A |
| 2026-03-06 | Fmr LLC | 11.1% | SCHEDULE 13G |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-17 | Two Seas Capital LP | 6.8% | SCHEDULE 13G |
| 2026-05-06 | Fmr LLC | 15% | SCHEDULE 13G/A |
| 2026-05-15 | Bvf Partners L P | 9.8% | SCHEDULE 13G/A |
| 2026-07-29 | BlackRock, Inc. | 7.8% | SCHEDULE 13G |
| 2026-07-31 | Vanguard Capital Management | 5.17% | SCHEDULE 13G |
| 2026-08-14 | Bvf Partners L P | 7.1% | SCHEDULE 13G/A |
| 2026-08-14 | Two Seas Capital LP | 9.1% | SCHEDULE 13G/A |
| 2026-09-28 | Two Seas Capital LP | 9.8% | SCHEDULE 13G/A |
Questions about who owns Nektar Therapeutics
Who owns Nektar Therapeutics?
On this page, 5 holders' latest ownership filings report 5% or more of Nektar Therapeutics: Fmr LLC (15%, Schedule 13G/A, filed 2026-05-06), Two Seas Capital LP (9.8%, Schedule 13G/A, filed 2026-09-28), BlackRock, Inc. (7.8%, Schedule 13G, filed 2026-07-29), Bvf Partners L P (7.1%, Schedule 13G/A, filed 2026-08-14) and Vanguard Capital Management (5.17%, Schedule 13G, filed 2026-07-31).
Who are the largest shareholders of Nektar Therapeutics?
By the share each holder's latest filing reports, the largest holders of Nektar Therapeutics on this page are Fmr LLC (15%), Two Seas Capital LP (9.8%) and BlackRock, Inc. (7.8%).
When did Fmr LLC buy into Nektar Therapeutics?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2026-03-06, reporting 11.1%; its latest, Schedule 13G/A filed 2026-05-06, reports 15%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 22 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Nektar Therapeutics
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 8, 2026 | Leadership change: Linda Rubinstein appointed, Chief Financial Officer | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Nektar Therapeutics. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.